Evommune Looks To Advance Broad Pipeline Of Autoimmune Drugs

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.

Emerging Company Profile: Evommune
Evommune is developing drugs for inflammatory conditions • Source: Shutterstock

Evommune, Inc. recently closed a $57.5m series B financing that it believes will position the company to advance multiple novel drugs for a variety of autoimmune diseases toward value-creating catalysts. The company’s lead asset is a topical IRAK4 inhibitor in Phase IIa development for atopic dermatitis, but the company has other novel systemic drugs it is aiming to bring into the clinic in the near-term.

“Our goal is to continue to drive a pipeline and not just have one program with a binary outcome,” CEO...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.